WORKING GROUP 2. DILI RISK STRATIFICATION
Leader (gerd.kullak@usz.ch)
University Hospital Zurich (Switzerland)
- Professor of Clinical Pharmacology and Toxicology, Director of the Department of Clinical Pharmacology and Toxicology, University Hospital Zurich
- Head of the regional pharmacovigilance centre at the University Hospital Zurich
- Global Head of Mechanistic Safety and Chair of the Hepatic Safety Team, Novartis Global Drug Development
- Work package lead of the DILI work package in the IMI SAFE-T consortium and the IMI TransBioLine consortium
- The risk of DILI is strongly dependent on the drug administered and on host factors that determine the individual response. Risk stratification should focus on the following:
- Characterization of the risk profile and mechanism of toxicity of newer hepatotoxic agents, e.g. tyrosine kinase inhibitors or immune checkpoint inhibitors
- Evaluation of novel biomarkers for DILI for the prediction of severe DILI in patients
- Investigation of individual susceptibility factors that anticípate a risk for DILI